---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-24-000012"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2024-01-25T23:59:59+00:00"
generated_at: "2026-06-06T18:23:59.768499+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zentalis appoints Diana Hausman as CMO, Kyle Rasbach as CBO; receives Nasdaq notice on audit committee

## Summary
- Diana Hausman appointed CMO effective Jan 19, 2024; succeeds Carrie Brownstein who stepped down for personal reasons.
- Kyle Rasbach appointed CBO; formerly portfolio manager at Eventide Asset Management.
- Dr. Hausman resigned from Board and Audit Committee, causing Nasdaq audit committee independence non-compliance.
- Company has 180 days (by July 17, 2024) to appoint a third independent director to regain compliance.
- Dr. Brownstein receives severance: 10 months base salary + 2023 & prorated 2024 target bonuses, 12 months COBRA.

## SEC filing metadata
- accession: 0001725160-24-000012
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2024-01-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000012/0001725160-24-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000012/zntl-20240119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-24-000012
- JSON: https://secwatch.observer/filing/0001725160-24-000012.json
- Plain text: https://secwatch.observer/filing/0001725160-24-000012.txt

## Key facts
- Executive change
  Diana Hausman was appointed as Chief Medical Officer at Zentalis Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On January 25, 2024, Zentalis Pharmaceuticals, Inc. (the “Company” or “Zentalis”) announced that Diana Hausman, M.D., a member of the Company’s Board of Directors (the “Board”), had succeeded Carrie Brownstein, M.D. as Chief Medical Officer of the Company, effective January 19, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000012/0001725160-24-000012-index.htm
- Executive change
  Carrie Brownstein departed as Chief Medical Officer at Zentalis Pharmaceuticals, Inc..
  - Action: stepped down
  - Role: Chief Medical Officer
  source text: Dr. Brownstein stepped down for personal reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000012/0001725160-24-000012-index.htm
- Executive change
  Diana Hausman resigned as Director at Zentalis Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: Dr. Hausman resigned from the Board, the Audit Committee of the Board (“Audit Committee”), and the Nominating and Corporate Governance Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000012/0001725160-24-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.